The German biotechnology company BioNTech has entered into a partnership with the Chinese Shanghai Fosun Pharmaceutical Group.

That company will annually produce up to 1 billion doses of the corona vaccine developed by BioNTech in China.

Until now, Fosun was only BioNTech's distribution partner.

Both parties are investing $ 100 million in the partnership.

Shanghai Fosun does this in the form of money and a factory for production.

BioNTech is bringing in manufacturing technology and a license to make its vaccine.

BioNTech and partner Pfizer anticipate production of up to 3 billion doses of the corona vaccine this year.

There could be a little more next year.

The two companies are working together on the vaccine for the world except China, Hong Kong and Macau.

In those areas, Fosun is BioNTech's partner.

It is not immediately clear when production will start in China.

It is also not certain whether the 1 billion doses per year have already been included in BioNTech's estimates.